RepliCel Life Sciences Profit margin
What is the Profit margin of RepliCel Life Sciences?
The Profit margin of RepliCel Life Sciences, Inc. is -88.14%
What is the definition of Profit margin?
Profit margin is a measure of profitability and is calculated by finding the net profit as a percentage of the revenue.
lfy (last fiscal year)
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Profit margin of companies in the Health Care sector on TSXV compared to RepliCel Life Sciences
What does RepliCel Life Sciences do?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Companies with profit margin similar to RepliCel Life Sciences
- Pulmonx Corp has Profit margin of -88.60%
- Capricor Therapeutics Inc has Profit margin of -88.52%
- Axsome Therapeutics Inc has Profit margin of -88.41%
- Zhicheng Technology has Profit margin of -88.36%
- China Dredging Environment Protection has Profit margin of -88.31%
- MC Mining has Profit margin of -88.18%
- RepliCel Life Sciences has Profit margin of -88.14%
- Cutera Inc has Profit margin of -88.05%
- Values Cultural Invest Ltd has Profit margin of -88.02%
- Cree has Profit margin of -87.97%
- Mirum Pharmaceuticals Inc has Profit margin of -87.68%
- Limitless Venture has Profit margin of -87.50%
- Vicinity Motor has Profit margin of -87.30%